dr. cortes discusses the use of ponatinib in types of leukemia
Published 11 years ago • 268 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
5:22
bosutinib versus ponatinib in r/r cml
-
1:56
dr. cortes on ponatinib in patients with cml and ph all
-
1:01
dr. cortes discusses ponatinib as initial therapy for cml
-
8:00
dr. cortes discusses approval of ponatinib for adults with chronic-phase cml
-
0:57
dr. cortes discusses tki cessation in cml
-
2:06
dr. jorge cortes discusses the ponatinib ph all and cml evaluation (pace) trial
-
5:03
role of ponatinib in treatment of r/r cml
-
1:55
role of next-generation sequencing in neuroendocrine tumors (nets)
-
1:38
an update on the optic study: adjusting the dose of ponatinib for cp-cml
-
3:20
case 1: ponatinib in chronic-phase cml
-
24:30
management of thrombosis risk with ponatinib and other tkis for cml?
-
2:03
dr. cortes discusses the quantum-r data with quizartinib in aml
-
1:43
dr. jorge cortes on the phase ii ponatinib pace trial
-
7:42
ponatinib: promises and challenges
-
6:36
jorge e cortes, asco20: 5-year analysis of the phase ii pace trial of ponatinib in ph leukemia
-
5:10
jorge e cortes asco20: interim analysis of the phase ii optic trial of ponatinib in cp-cml
-
1:43
dr. cortes on the safety profile of ruxolitinib in mpns
-
6:36
jorge e cortes, asco20: 5-year analysis of the phase ii pace trial of ponatinib in ph leukemia
-
10:12
switching therapy in chronic myeloid leukemia